Family Navigates High Cost of Alzheimer's Drug Slowing Husband's Decline
A couple shares their experience with a groundbreaking drug that has slowed their 56-year-old husband's dementia, highlighting the financial burden of out-of-pocket costs.
A family is sharing their story about a new Alzheimer's drug that has significantly slowed the cognitive decline of their 56-year-old husband, Nick, but underscores the substantial financial strain it imposes. Nick, who was always a proficient speller, began to falter, asking his wife for spellings and forgetting recent events.
Blood, urine tests, and brain scans confirmed Nick had young-onset Alzheimer's disease. He is among an estimated 70,000 Britons living with the condition. Initially, Nick was prescribed donepezil by the National Health Service (NHS). However, he could not tolerate the highest, most effective dose because the drug can slow the heart rate, and Nick's resting heart rate, as a lifelong runner, is already low.
The couple ultimately chose to pay for a new drug, Lecanemab, which has garnered attention as one of the first medications shown to slow the progression of Alzheimer's. This decision comes with an annual cost of approximately £80,000. Despite the financial challenge, the drug has allowed Nick and his wife, Nicky, to resume enjoying their life together, finding a way to manage his decline.
Nick's early symptoms were subtle, nearly missed by his family. His initial forgetfulness and struggles with spelling were early indicators of the disease's onset. The new treatment has provided a renewed sense of normalcy for the couple, enabling them to continue their life together while navigating the complexities of the disease.
